References
- Andre F , CiccoliniJ, SpanoJP et al. Personalized medicine in oncology: where do we come from and where are we going? Pharmacogenomics 14(8) , 931–939 (2013).
- Ciccolini J , GrossE, DahanL, LacarelleB, MercierC. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin. Colorectal Cancer9(4) , 224–228 (2010).
- Fenoglio-Preiser CM , WangJ, StemmermannGN, NoffsingerA. TP53 and gastric carcinoma: a review. Hum. Mutat.21(3) , 258–270 (2003).
- Yang M , GuoY, ZhangX et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 28(9) , 1996–2001 (2007).
- Huang ZH , HuaD, LiLH, ZhuJD. Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. J. Cancer Res. Clin. Oncol.134(10) , 1129–1134 (2008).
- Kim JG , SohnSK, ChaeYS et al. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother. Pharmacol.64(2) , 355–360 (2009).
- Vogelstein B , KinzlerKW. p53 function and dysfunction. Cell70(4) , 523–526 (1992).
- Francisco G , MenezesPR, Eluf-NetoJ, ChammasR. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case–control studies. Int. J. Cancer129(4) , 920–930 (2011).
- Longley DB , HarkinDP, JohnstonPG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer3(5) , 330–338 (2003).
- Zaanan A , Cuilliere-DartiguesP, GuillouxA et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann. Oncol. 21(4) , 772–780 (2010).
- Kelly CM , PritchardKI. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J. Natl Cancer Inst.104(6) , 427–428 (2012).
- Zanger UM , KleinK. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front. Genet.4 , 24 (2013).
- George Priya Doss C , RajasekaranR, ArjunP, SethumadhavanR. Prioritization of candidate SNPs in colon cancer using bioinformatics tools: an alternative approach for a cancer biologist. Interdiscip. Sci.2(4) , 320–346 (2010).
- Innocenti F , RatainMJ. “Irinogenetics” and UGT1A: from genotypes to haplotypes. Clin. Pharmacol. Ther.75(6) , 495–500 (2004).
- Kim TW , InnocentiF. Insights, challenges, and future directions in irinogenetics. Ther. Drug Monit.29(3) , 265–270 (2007).
- Hoskins JM , GoldbergRM, QuP, IbrahimJG, McLeodHL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst.99(17) , 1290–1295 (2007).
- Mathijssen RH , GurneyH. Irinogenetics: how many stars are there in the sky? J. Clin. Oncol.27(16) , 2578–2579 (2009).
- Andre F , CiccoliniJ, SpanoJP et al. Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics 14(8) , 931–939 (2013).